RNA Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of novel mRNA delivery systems for therapeutic proteins and vaccines. Its pipeline includes vaccine candidates and therapeutic constructs for Alzheimers disease, Type I diabetes, HIV (active and latent stages), neurodegenerative disorders, and cancer immunotherapy. The company positions itself to carry its programs through IND-stage development before licensing to larger pharmaceutical firms. In August 2024, the company announced that it had received written feedback from the U.S. FDA in response to its Pre-IND questions, validating its development path for an mRNA-based delivery of therapeutic proteins. RNA Therapeutics also engages in early-stage vaccine development and collaborates with academic groups (e.g. with UTMBs lab) on mRNA vaccine platforms.
